Search
forLearn
5 / 801 resultslearn KX-826
learn Desoximetasone
learn acetyl methionine
learn glutamic acid
Research
5 / 137 results
research Roles for Msx and Dlx homeoproteins in vertebrate development
Msx and Dlx genes are crucial for development, controlling cell behaviors like growth and differentiation through their roles as gene regulators.
research Does Vitamin D play a role on Msx1 homeoprotein expression involving an endogenous antisense mRNA?*1
Vitamin D affects Msx1 protein expression and may influence mineralized tissue health.
research Epidermal Dysplasia and Abnormal Hair Follicles in Transgenic Mice Overexpressing Homeobox Gene MSX-2
Overexpressing the MSX-2 gene in mice causes skin and hair growth issues.
research Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation
Msx2 deficiency in mice leads to bone growth and organ development problems.
research Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective
Controlling cellular changes can enable safe rejuvenation without cancer risk.
Community Join
5 / 1000+ resultscommunity KX-826 , a small change in the pipeline
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.
community KX-826 1% Phase II Results from China Just Dropped
KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.
community KX-826 Pyrilutamide1% coming soon
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community Jxl069 (pp405 api) week 8 update
The user shared minimal results from using JXL-069 for hair loss, noting a slight lengthening of vellus hairs and plans to switch to a prodrug variant due to limited effectiveness. They also mentioned using finasteride and minoxidil, which have plateaued in results.